Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury

F. Simko, T. Baka, K. Repova, S. Aziriova, K. Krajcirovicova, L. Paulis, M. Adamcova

. 2021 ; 35 (4) : 744-748. [pub] 20201107

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003996

Grantová podpora
PROGRES Q40/5 Univerzita Karlova v Praze
1/0035/19 Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
2/0112/19 Vedecká Grantová Agentúra MŠVVaŠ SR a SAV

This study investigated whether ivabradine, a selective If current inhibitor reducing heart rate (HR), is able to improve survival and prevent left ventricular (LV) remodeling in isoproterenol-induced heart damage. Wistar rats were treated for 6 weeks: controls (n = 10), ivabradine (10 mg/kg/day orally; n = 10), isoproterenol (5 mg/kg/day intraperitoneally; n = 40), and isoproterenol plus ivabradine (n = 40). Isoproterenol increased mortality, induced hypertrophy of both ventricles and LV fibrotic rebuilding, and reduced systolic blood pressure (SBP). Ivabradine significantly increased survival rate (by 120%) and prolonged average survival time (by 20%). Furthermore, ivabradine reduced LV weight and hydroxyproline content in soluble and insoluble collagen fraction, reduced HR and attenuated SBP decline. We conclude that ivabradine improved survival in isoproterenol-damaged hearts.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003996
003      
CZ-PrNML
005      
20220127145642.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/fcp.12620 $2 doi
035    __
$a (PubMed)33098700
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, 81108, Slovak Republic $u 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, 83305, Slovak Republic $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, 84505, Slovak Republic
245    10
$a Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury / $c F. Simko, T. Baka, K. Repova, S. Aziriova, K. Krajcirovicova, L. Paulis, M. Adamcova
520    9_
$a This study investigated whether ivabradine, a selective If current inhibitor reducing heart rate (HR), is able to improve survival and prevent left ventricular (LV) remodeling in isoproterenol-induced heart damage. Wistar rats were treated for 6 weeks: controls (n = 10), ivabradine (10 mg/kg/day orally; n = 10), isoproterenol (5 mg/kg/day intraperitoneally; n = 40), and isoproterenol plus ivabradine (n = 40). Isoproterenol increased mortality, induced hypertrophy of both ventricles and LV fibrotic rebuilding, and reduced systolic blood pressure (SBP). Ivabradine significantly increased survival rate (by 120%) and prolonged average survival time (by 20%). Furthermore, ivabradine reduced LV weight and hydroxyproline content in soluble and insoluble collagen fraction, reduced HR and attenuated SBP decline. We conclude that ivabradine improved survival in isoproterenol-damaged hearts.
650    _2
$a zvířata $7 D000818
650    _2
$a kardiotonika $x aplikace a dávkování $x farmakologie $7 D002316
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a srdeční selhání $x farmakoterapie $7 D006333
650    _2
$a isoprenalin $7 D007545
650    _2
$a ivabradin $x aplikace a dávkování $x farmakologie $7 D000077550
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a infarkt myokardu $x patofyziologie $7 D009203
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a funkce levé komory srdeční $x účinky léků $7 D016277
650    _2
$a remodelace komor $x účinky léků $7 D020257
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baka, Tomas $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, 81108, Slovak Republic
700    1_
$a Repova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, 81108, Slovak Republic
700    1_
$a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, 81108, Slovak Republic
700    1_
$a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, 81108, Slovak Republic
700    1_
$a Paulis, Ludovit $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, 81108, Slovak Republic
700    1_
$a Adamcova, Michaela $u Department of Physiology, School of Medicine, Charles University, Hradec Kralove, 50003, Czech Republic
773    0_
$w MED00001866 $t Fundamental & clinical pharmacology $x 1472-8206 $g Roč. 35, č. 4 (2021), s. 744-748
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33098700 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145639 $b ABA008
999    __
$a ok $b bmc $g 1751455 $s 1155145
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 4 $d 744-748 $e 20201107 $i 1472-8206 $m Fundamental & clinical pharmacology $n Fundam Clin Pharmacol $x MED00001866
GRA    __
$a PROGRES Q40/5 $p Univerzita Karlova v Praze
GRA    __
$a 1/0035/19 $p Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
GRA    __
$a 2/0112/19 $p Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace